Reply to "GLP1RA versus SGLT2i tended to have more favorable ischemic outcomes including stroke?"

被引：0
|
作者：
Hwang, In-Chang [1 ,2 ]
Kim, Chee Hae [3 ]
机构：
[1] Seoul Natl Univ, Cardiovasc Ctr, Dept Internal Med, Bundang Hosp, Seongnam, Gyeonggi, South Korea
[2] Seoul Natl Univ, Div Cardiol, Bundang Hosp, Seongnam, Gyeonggi, South Korea
[3] Div Cardiol, Dept Internal Med, VHS Med Ctr, Seoul, South Korea
来源：
INTERNATIONAL JOURNAL OF CARDIOLOGY | 2022年 / 369卷
关键词：
D O I：
10.1016/j.ijcard.2022.08.047
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：12 / 12
页数：1
相关论文
共 50 条
  • [21] Benefit of Dual Therapy with GLP-1 RA and SGLT2i on Cardiovascular Outcomes in Type 2 Diabetes
    Zareini, Bochra
    Gerds, Thomas A.
    Sorensen, Kathrine K.
    Clemmensen, Kim K. B.
    Kvist, Kajsa
    David, Jens-Peter
    Torp-Pedersen, Christian
    DIABETES, 2023, 72
  • [22] Benefit of dual therapy with GLP-1 RA and SGLT2i on cardiovascular outcomes in type 2 diabetes
    Zareini, B.
    Gerds, T.
    Sorensen, K. K.
    Clemmensen, K. K. B.
    Kvist, K.
    David, J. -P.
    Torp-Pedersen, C.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S30 - S30
  • [23] Benefit of Dual Therapy with GLP-1 RA and SGLT2i on Renal Outcomes in Type 2 Diabetes
    Zareini, Bochra
    Gerds, Thomas A.
    Sorensen, Kathrine K.
    Clemmensen, Kim K. B.
    Kvist, Kajsa
    David, Jens-Peter
    Torp-Pedersen, Christian
    DIABETES, 2023, 72
  • [24] IMPLEMENTING ADHERENCE TO SGLT2I AND GLP1RA IN PATIENTS WITH CARDIOVASCULAR DISEASE: FINDINGS FROM A PHARMACIST-DRIVEN CARDIODIABETES CLINIC PROGRAM
    Lee, Kevin
    Ikram, Mashaal
    Mishkel, Gregory J.
    Ng, Elaine
    Krupa, Edyta
    Zahvolskyy, Lidiya
    Davidson, David Jeremy
    Gordon, Robert Andrew
    Billings, Liana
    Sarav, Menaka
    Block, Romy
    Erwin, John P., III
    Qamar, Arman
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 83 (13) : 1938 - 1938
  • [25] Molecular Mechanisms Underlying the Cardiovascular Benefits of SGLT2i and GLP-1RA
    Khat, Dorrin Zarrin
    Husain, Mansoor
    CURRENT DIABETES REPORTS, 2018, 18 (07)
  • [26] Molecular Mechanisms Underlying the Cardiovascular Benefits of SGLT2i and GLP-1RA
    Dorrin Zarrin Khat
    Mansoor Husain
    Current Diabetes Reports, 2018, 18
  • [27] Early combination therapy with SGLT2i and GLP-1 RA or dual GIP/GLP-1 RA in type 2 diabetes
    Vale, Catarina
    Lourenco, Ines Mariana
    Jordan, Gabriela
    Golovaty, Ilya
    Torres, Hugo
    Moin, Tannaz
    Buysschaert, Martin
    Neves, Joao Sergio
    Bergman, Michael
    DIABETES OBESITY & METABOLISM, 2024,
  • [28] Genetic Mimics of GLP-1Ra and SGLT2i Therapy, Heart Failure and Chronic Kidney Disease Outcomes
    Remala, Subbaramireddy
    Liang, Liming
    Shah, Amil
    Buckley, Leo
    CIRCULATION, 2024, 150
  • [29] Impact of Endocrine E-Consultation on SGLT2i and GLP-1 RA Prescription
    Rasheed, Amna
    Kompala, Tejaswi
    Neinstein, Aaron B.
    DIABETES, 2021, 70
  • [30] Gaps in Guideline-Indicated Prescribing of GLP1RA/SGLT2i in Patients with T2DM and Cardiorenal Disease according to ADA Standards of Care
    Lingvay, Ildiko
    Bowen, Michael E.
    Mai, Christine
    Marble, Kelsea
    Pak, Jonathan
    Basit, Mujeeb A.
    DIABETES, 2023, 72
12345